Tag : LOW-DENSITY LIPOPROTEIN CHOLESTEROL

CONFERENCE UPDATE

LDL-C reduction with lerodalcibep in patients at very high or high risk for CVD: The phase 3 LIBerate-HR study
Lerodalcibep is a third-generation proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor that prevents PCSK9 from binding to low-density lipoprotein receptors (LDLRs). Low-density lipoprotein-cholesterol (LDL-C) clearance from the bloodstream is enhanced as a result of LDLR degradation being blocked. Compared to monoclonal antibodies (mAbs), lerodalcibep is smaller in size and has a higher solubility, enabling prolonged and stable LDL-C reductions. In a prior phase 2 trial, lerodalcibep at a dose of 300mg monthly was shown to be effective in lowering LDL-C by >70%.
NEWS AND PERSPECTIVE

Bempedoic acid receives FDA approvaal for expanded indication in CVD Prevention
Bempedoic acid inhibits ATP citrate lyase, an enzyme upstream of 3-hydroxy-3-methalglutaryl-coenzyme (HMG-CoA) reductase which is the rate-limiting step of cholesterol biosynthesis. This reduces hepatic cholesterol synthesis and raises LDL receptor expression, increasing the clearance of LDL-C from the circulation.